By Paul Ziobro
Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms.
Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies.
Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
January 28, 2025 16:14 ET (21:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.